We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-1.26%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$7.91B
AUM Growth
-$2.56B
Cap. Flow
+$5.6B
Cap. Flow %
70.85%
Top 10 Hldgs %
34.65%
Holding
156
New
13
Increased
15
Reduced
59
Closed
23

Top Buys

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$7.7B
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$114M
3
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$76.7M
4
FOLD
Amicus Therapeutics
FOLD
+$76.6M
5
SCPH
scPharmaceuticals
SCPH
+$48.1M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$172M
2
AET
Aetna Inc
AET
+$163M
3
BIIB icon
Biogen
BIIB
+$128M
4
MRK icon
Merck
MRK
+$108M
5
GILD icon
Gilead Sciences
GILD
+$107M

Sector Composition

Rank Sector Weight
1 Healthcare 91.1%
2 Financials 1.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XTNT icon
126
Xtant Medical Holdings
XTNT
$59.7M
$272K ﹤0.01%
396,199
+356,579
+900% +$2.81M
XYLO
127
DELISTED
Xylo Technologies
XYLO
$79K ﹤0.01%
375
– –
BMY icon
128
CALL
Bristol-Myers Squibb
BMY
$130B
– –
-150,000
Closed -$9.56M
CRSP icon
129
CRISPR Therapeutics
CRSP
$4.68B
– –
-372,191
Closed -$6.65M
CBIO
130
Crescent Biopharma
CBIO
$608M
– –
-3,376
Closed -$4.72M
HALO icon
131
Halozyme
HALO
$9.9B
– –
-350,000
Closed -$6.08M
HCA icon
132
HCA Healthcare
HCA
$92.8B
– –
-187,400
Closed -$14.9M
INCY icon
133
Incyte
INCY
$26B
– –
-1,476,000
Closed -$172M
INCY icon
134
PUT
Incyte
INCY
$26B
– –
-200,000
Closed -$23.3M
MCRB icon
135
CALL
Seres Therapeutics
MCRB
$46.5M
– –
-3,750
Closed -$1.2M
NBIX icon
136
Neurocrine Biosciences
NBIX
$18.4B
– –
-284,841
Closed -$17.5M
TEVA icon
137
Teva Pharmaceuticals
TEVA
$36.9B
– –
-405,500
Closed -$7.14M
ZBH icon
138
Zimmer Biomet
ZBH
$18.5B
– –
-50,470
Closed -$5.74M
LUMO
139
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-5,556
Closed -$509K
LUMO
140
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-92,364
Closed -$8.46M
ARAV
141
CALL
DELISTED
Aravive, Inc. Common Stock
ARAV
– –
-8,333
Closed -$123K
ICPT
142
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-386,380
Closed -$22.4M
INFI
143
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-2,207,245
Closed -$2.94M
OTIC
144
DELISTED
Otonomy, Inc.
OTIC
– –
-644,074
Closed -$2.09M
MNK
145
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
– –
-1,472,700
Closed -$55M
ONCE
146
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
– –
-430,016
Closed -$38.3M
SGYP
147
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
– –
-13,621,443
Closed -$39.5M
ROKA
148
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
– –
-201,617
Closed -$147K
SHPG
149
PUT
DELISTED
Shire pic
SHPG
– –
-100,000
Closed -$15.3M
DMTX
150
DELISTED
Dimension Therapeutics, Inc
DMTX
– –
-5,397,698
Closed -$32.4M
2 3 4 5
6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q4 2017 Portfolio in Review

As of Q4 2017, OrbiMed held 156 positions worth $7.91B, down 24% from $10.5B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

OrbiMed deployed $5.6B of net new capital in Q4 2017, opening 13 new positions and adding to 15 existing holdings. Its largest new stake was Rhythm Pharmaceuticals: 2,901,295 shares worth $43.5M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 91% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Aetna Inc, an estimated $163M trimmed.

  • OrbiMed's largest Q4 2017 buy was Rhythm Pharmaceuticals: 2,901,295 shares worth $43.5M.
  • OrbiMed added most to Loxo Oncology, Inc in Q4 2017, an estimated $7.7B increase.
  • OrbiMed's biggest Q4 2017 reduction was Aetna Inc, cutting an estimated $163M.
  • OrbiMed fully exited Incyte in Q4 2017, selling an estimated $172M.
  • OrbiMed's ten largest holdings make up 35% of its $7.91B portfolio in Q4 2017.
  • OrbiMed opened 13 new positions and closed 23 in Q4 2017.
  • OrbiMed's portfolio value fell 24% quarter-over-quarter to $7.91B.

Based on OrbiMed's 13F filing for Q4 2017, filed 14 Feb 2018.